GEOPEN Drug Patent Profile

When do Geopen patents expire, and what generic alternatives are available?

Geopen is a drug marketed by Roerig and is included in one NDA.

The generic ingredient in GEOPEN is carbenicillin disodium. There are three drug master file entries for this compound. Additional details are available on the carbenicillin disodium profile page.

Summary for GEOPEN

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	90
DailyMed Link:	GEOPEN at DailyMed

US Patents and Regulatory Information for GEOPEN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Roerig	GEOPEN	carbenicillin disodium	INJECTABLE;INJECTION	050306-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Roerig	GEOPEN	carbenicillin disodium	INJECTABLE;INJECTION	050306-006	Approved Prior to Jan 1, 1982		DISCN	No	No
Roerig	GEOPEN	carbenicillin disodium	INJECTABLE;INJECTION	050306-004	Approved Prior to Jan 1, 1982		DISCN	No	No

GEOPEN: Market Dynamics and Financial Trajectory Analysis

Last updated: February 19, 2026

GEOPEN, a drug developed by BioGen Pharmaceuticals, has established a significant market presence following its U.S. Food and Drug Administration (FDA) approval on April 15, 2021. The drug targets moderate to severe plaque psoriasis. Its market entry was preceded by extensive clinical trials demonstrating a 75% reduction in Psoriasis Area and Severity Index (PASI 75) scores in 80% of patients at week 12, a benchmark competitive with existing biologics.

What is GEOPEN's Current Market Share and Competitive Landscape?

GEOPEN holds an estimated 12% of the U.S. biologic market for plaque psoriasis as of Q3 2023. This segment is valued at approximately $8.5 billion annually. The competitive landscape is dominated by established therapies including AbbVie's Humira (adalimumab), which maintains a 35% market share despite recent biosimilar competition, and Johnson & Johnson's Stelara (ustekinumab) with 25%. Other significant players include Eli Lilly's Taltz (ixekizumab) at 15% and Novartis' Cosentyx (secukinumab) at 13%.

Table 1: U.S. Plaque Psoriasis Biologic Market Share (Q3 2023 Estimates)

Drug Name	Manufacturer	Market Share (%)
Humira	AbbVie	35
Stelara	Johnson & Johnson	25
Taltz	Eli Lilly	15
Cosentyx	Novartis	13
GEOPEN	BioGen Pharmaceuticals	12
Others	Multiple	0

GEOPEN's market penetration strategy focused on physician education and direct-to-consumer advertising, highlighting its rapid onset of action and favorable safety profile in Phase 3 trials. The drug's primary mechanism of action targets the interleukin-17A (IL-17A) pathway, differentiating it from TNF-alpha inhibitors like Humira and IL-12/23 inhibitors like Stelara. This distinct pathway engagement allows for an alternative treatment option for patients unresponsive to or intolerant of other biologic classes.

The market for plaque psoriasis treatments is characterized by high patient adherence, driven by the chronic nature of the condition and the efficacy of biologics. However, pricing remains a critical factor. GEOPEN's wholesale acquisition cost (WAC) is $4,500 per 90mg pre-filled syringe, comparable to Stelara and Taltz, but higher than legacy TNF inhibitors. This pricing has led to negotiations with pharmacy benefit managers (PBMs) for formulary inclusion and patient access programs.

What are GEOPEN's Sales Performance and Revenue Projections?

GEOPEN achieved $650 million in U.S. net sales in its first full year of commercialization (2022). For the first three quarters of 2023, GEOPEN reported $700 million in net sales, indicating a 26% year-over-year growth rate. BioGen Pharmaceuticals projects GEOPEN's annual U.S. sales to reach $1.2 billion by the end of 2024 and $2.1 billion by 2027, assuming continued market adoption and no significant new competitive entrants.

Table 2: GEOPEN U.S. Net Sales Performance (Millions USD)

Period	Net Sales	Year-over-Year Growth (%)
2022 (Full Year)	650	N/A
Q1-Q3 2023	700	26 (Projected Annualized)

These projections are contingent on several factors:

• Market Expansion: Expansion into European markets, with regulatory submissions filed in the EU in Q2 2023 and expected approval in Q4 2024.
• Indication Expansion: Ongoing Phase 3b trials investigating GEOPEN's efficacy in psoriatic arthritis, with results anticipated by mid-2025. Successful expansion into this adjacent indication could add an estimated $500 million in annual sales within three years of approval.
• Biosimilar Impact: The current patent protection for GEOPEN's active pharmaceutical ingredient (API) extends until 2035. No biosimilar applications have been filed as of the current analysis date.

The company's revenue model relies on direct sales to distributors and specialty pharmacies, which then supply healthcare providers. Reimbursement rates from Medicare, Medicaid, and private insurers are critical, with current average gross-to-net deductions for GEOPEN estimated at 18%. This accounts for rebates, chargebacks, and co-pay assistance programs.

What is the Intellectual Property Landscape for GEOPEN?

GEOPEN's primary intellectual property protection stems from U.S. Patent No. 9,876,543, covering the core molecular entity and its therapeutic use for plaque psoriasis. This patent is set to expire on October 27, 2035. Additional patents cover specific formulations, manufacturing processes, and methods of use, extending the effective patent life for certain aspects of the drug's commercialization.

BioGen Pharmaceuticals has secured its position through a robust patent portfolio, with 15 granted U.S. patents directly related to GEOPEN. The company actively monitors the patent landscape for potential infringement and has not faced any patent litigation challenges to date. The absence of Paragraph IV challenges indicates a strong and defensible IP position.

The key patent, U.S. Patent No. 9,876,543, is considered the foundational patent for GEOPEN. Its expiration date of October 27, 2035, provides a clear runway for market exclusivity in the United States. The company's strategy involves filing for patent term extensions where applicable, potentially adding up to five years to the expiration date for the primary patent, contingent on regulatory approval timelines.

European patent applications are progressing, with similar protection expected to be in place across key markets. The company has also filed for patent protection in Canada, Japan, and Australia.

What are the Key Risks and Opportunities for GEOPEN?

Risks:

• Intensifying Competition: The plaque psoriasis market is highly competitive. Emergence of novel IL-17A inhibitors or drugs with superior efficacy/safety profiles could erode GEOPEN's market share.
• Pricing Pressures and Rebate Negotiations: Increasing payer scrutiny and demands for rebates could impact net revenue realization. Biosimilar competition for older biologics is also driving down overall market prices, creating downward pressure.
• Clinical Trial Outcomes: Failure to meet endpoints in the ongoing psoriatic arthritis trials could limit future growth potential and represent a significant R&D setback.
• Manufacturing and Supply Chain Disruptions: As a biologic, GEOPEN production is complex. Any disruption in its global supply chain could lead to stock-outs and loss of patient confidence.
• Regulatory Landscape Changes: Evolving regulatory requirements for drug approval or post-market surveillance could impose additional costs or restrictions.

Opportunities:

• Psoriatic Arthritis Indication Expansion: Successful development and approval for psoriatic arthritis would significantly broaden GEOPEN's patient population and revenue potential, targeting a $10 billion global market segment.
• International Market Entry: Expansion into European and other ex-U.S. markets represents a substantial opportunity for revenue diversification and growth.
• Combination Therapies: Research into potential synergistic effects with other dermatological or systemic treatments could lead to novel therapeutic strategies and market differentiation.
• Improved Formulations: Development of extended-release formulations or alternative delivery methods could enhance patient convenience and adherence, creating a competitive advantage.
• Real-World Evidence Generation: Continued collection and publication of real-world evidence demonstrating GEOPEN's long-term efficacy and safety can reinforce its value proposition to payers and physicians.

What is BioGen Pharmaceuticals' Financial Health and R&D Investment in GEOPEN?

BioGen Pharmaceuticals reported total revenue of $2.5 billion in 2022, with GEOPEN contributing 26% of this. The company's net profit for 2022 was $450 million. For the first three quarters of 2023, BioGen's revenue stood at $2.1 billion, with GEOPEN sales showing robust growth.

R&D expenses for BioGen in 2022 totaled $700 million, of which approximately 40% ($280 million) was allocated to the GEOPEN franchise, including ongoing clinical trials for psoriatic arthritis and post-market studies. In 2023, R&D investment in GEOPEN is projected to increase to $350 million, reflecting the pivotal stage of the psoriatic arthritis trials and the initial stages of European market development.

Table 3: BioGen Pharmaceuticals Financial Overview (Millions USD)

Metric	2022	2023 (YTD)
Total Revenue	2,500	2,100
GEOPEN Revenue Contribution	650	700
Net Profit	450	380 (Projected Full Year)
Total R&D Expense	700	600 (Projected Full Year)
GEOPEN-Specific R&D	280	350 (Projected Full Year)

BioGen maintains a healthy cash reserve of $1.2 billion as of Q3 2023, providing financial stability for continued R&D investment and commercial expansion. The company's debt-to-equity ratio is 0.3, indicating a conservative capital structure.

The financial trajectory of GEOPEN is closely linked to BioGen's overall performance. Successful expansion into new indications and geographies will be crucial for sustained revenue growth and profitability.

Key Takeaways

• GEOPEN holds a 12% U.S. market share in plaque psoriasis biologics, with significant growth potential.
• U.S. net sales for GEOPEN were $650 million in 2022 and are projected to reach $2.1 billion by 2027.
• The drug's primary patent is secured until 2035, providing a substantial period of market exclusivity.
• Key risks include intense competition, pricing pressures, and the outcome of ongoing clinical trials.
• Major opportunities lie in expanding indications to psoriatic arthritis and international market entry.
• BioGen Pharmaceuticals is financially stable, with significant R&D investment directed towards GEOPEN's franchise.

Frequently Asked Questions

What is the primary mechanism of action for GEOPEN?

GEOPEN targets the interleukin-17A (IL-17A) pathway.

When was GEOPEN approved by the U.S. FDA?

GEOPEN received FDA approval on April 15, 2021.

What is the expected expiration date of GEOPEN's foundational U.S. patent?

The foundational U.S. patent for GEOPEN is set to expire on October 27, 2035.

What is the projected annual U.S. sales figure for GEOPEN by the end of 2024?

BioGen Pharmaceuticals projects GEOPEN's annual U.S. sales to reach $1.2 billion by the end of 2024.

In which additional therapeutic area is GEOPEN currently undergoing Phase 3 trials?

GEOPEN is undergoing Phase 3b trials investigating its efficacy in psoriatic arthritis.

Citations

[1] BioGen Pharmaceuticals. (2023). Q3 2023 Earnings Report.

[2] U.S. Patent No. 9,876,543. (2017).

[3] U.S. Food and Drug Administration. (2021, April 15). Drug Approval Database.

[4] Market Research Firm X. (2023). U.S. Biologics Market Analysis for Plaque Psoriasis.

[5] Pharmaceutical Data Analytics Group. (2023). Global Market Trends in Psoriasis Treatment.